(NYSE:KEX), Fourth quarter 2024 GAAP earnings per share of $0.74, and fourth quarter 2024 adjusted earnings per share(1) of $1.29. Fourth quarter 2024 inland marine term contracts repriced higher in the 6-9% range year-over-year. Kirby repurchased 286,697 shares at an average price of $116.16 for $33.3 million and reduced debt balances by $105 million in […]
(NASDAQ:VIGL), WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) — Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on February 6, 2025, at 10:30
(NASDAQ:HOOK),(LSE – AIM:HOOK), HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HIV) Under the collaboration agreement, HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial Primary completion expected
(NASDAQ:ALGM), MANCHESTER, N.H., Jan. 30, 2025 (GLOBE NEWSWIRE) — Allegro MicroSystems, Inc. (“Allegro” or the “Company”) (Nasdaq: ALGM), a global leader in power and sensing semiconductor solutions for motion control and energy efficient systems, today announced financial results for its third quarter ended December 27, 2024. “We delivered on our commitments with third quarter sales
(NasdaqGM:TNGX), BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the Guggenheim SMID
(NASDAQ:DNTH), NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) — Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation and presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences
(TSX-V:ABI),(OTC US:ABMBF),(Other OTC:ABMBF), ROUYN-NORANDA, Quebec, Jan. 30, 2025 (GLOBE NEWSWIRE) — Abcourt Mines Inc. (“Abcourt” or the “Company”) (TSX Venture: ABI) (OTCQB : ABMBF) is pleased to announce the first assay results from its most recent drilling campaign currently underway on its Flordin property (100% ABI) in the Lebel-sur-Quevillon area. Highlights: The Adam mineralized zone
(NASDAQ:SASR), OLNEY, Md., Jan. 30, 2025 (GLOBE NEWSWIRE) — Sandy Spring Bancorp, Inc., (Nasdaq- SASR), the parent company of Sandy Spring Bank, announced that the board of directors declared a quarterly common stock dividend of $0.34 per share payable on February 19, 2025 to shareholders of record on February 12, 2025. This dividend is consistent
(NASDAQ:LTRX), IRVINE, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) — Lantronix Inc. (the “Company”) (NASDAQ: LTRX), a global leader of compute and connectivity for IoT solutions enabling AI Edge Intelligence, today announced it will release financial results from its fiscal 2025 second quarter, ended Dec. 31, 2024, after the close of the market on Thursday, Feb.
(NasdaqGM:KYMR), WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events: Guggenheim SMID Cap Biotechnology Conference